July 9, 2024Science Signaling

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

View Full Paper

Ask AI

Bookmark

Authors

JJJustin JacksonScholar Rock (United States)FSFrederick C. StreichScholar Rock (United States)APAjai PalScholar Rock (United States)

Discussion

Member takes

Implication

Preclinical study demonstrates that selective antibody LTBP-49247 halts renal fibrosis in rodent models, indicating matrix-bound TGF-β1 can be targeted without broad toxicity.

Key Points

The selective antibody LTBP-49247 halts renal fibrosis progression by inhibiting the activation of latent matrix-bound TGF-β1 complexes, preventing downstream tissue damage.
Structural and functional assays in two rodent models of renal fibrosis confirmed target engagement without triggering toxic effects typical of broad TGF-β pathway inhibitors.
These findings support targeting matrix-presented TGF-β1 to safely treat progressive fibrosing disorders; however, this rodent model requires further preclinical validation.

Cite This Study

Jackson et al. (2024) studied this question.

synapsesocial.com/papers/68e60e3db6db6435875a0c00 https://doi.org/10.1126/scisignal.adn6052

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates that selective antibody LTBP-49247 halts renal fibrosis in rodent models, indicating matrix-bound TGF-β1 can be targeted without broad toxicity.

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

Discussion

Member takes

Implication

Key Points

Cite This Study

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider